Clinical and pathological response to primary chemotherapy in operable breast cancer (Q33500269)

27 July 2017

title

Clinical and pathological response to primary chemotherapy in operable breast cancer (English)

1 reference

27 July 2017

1 reference

Chollet P

1

1 reference

27 July 2017

Charrier S

2

1 reference

27 July 2017

Brain E

3

1 reference

27 July 2017

Curé H

4

1 reference

27 July 2017

van Praagh I

5

1 reference

27 July 2017

Feillel V

6

1 reference

27 July 2017

de Latour M

7

1 reference

27 July 2017

Dauplat J

8

1 reference

27 July 2017

Misset JL

9

1 reference

27 July 2017

Ferrière JP

10

1 reference

27 July 2017

publication date

1 May 1997

1 reference

European Journal of Cancer

27 July 2017

published in

1 reference

27 July 2017

volume

33

1 reference

27 July 2017

issue

6

1 reference

27 July 2017

page(s)

862-866

1 reference

Multimodal treatment of locoregionally advanced breast cancer

27 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2900038-5

7 January 2021

Induction chemotherapy followed by breast conservation for locally advanced carcinoma of the breast

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2900038-5

7 January 2021

Primary chemotherapy to avoid mastectomy in tumors with diameters of three centimeters or more

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2900038-5

7 January 2021

Results of neoadjuvant chemotherapy and radiation therapy in the breast-conserving treatment of 250 patients with all stages of infiltrative breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2900038-5

7 January 2021

Preoperative chemotherapy: a model for studying the biology and therapy of primary breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2900038-5

7 January 2021

Primary chemotherapy for early and advanced breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2900038-5

7 January 2021

Primary chemotherapy in surgically resectable breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2900038-5

7 January 2021

Adjuvant treatment of node-positive breast cancer with cyclophosphamide, doxorubicin, fluorouracil, and vincristine versus cyclophosphamide, methotrexate, and fluorouracil: final report after a 16-year median follow-up duration.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2900038-5

7 January 2021

Neoadjuvant chemotherapy in 126 operable breast cancers

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2900038-5

7 January 2021

Early assessment of a new anticancer drug analogue--are the historical comparisons obsolete? The French experience with pirarubicin

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2900038-5

7 January 2021

Phase II trial of weekly intravenous vinorelbine in first-line advanced breast cancer chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2900038-5

7 January 2021

Histological grading and prognosis in breast cancer; a study of 1409 cases of which 359 have been followed for 15 years

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2900038-5

7 January 2021

Randomized trial of chemoendocrine therapy started before or after surgery for treatment of primary breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2900038-5

7 January 2021

High complete remission rates with primary neoadjuvant infusional chemotherapy for large early breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2900038-5

7 January 2021

Clinical use of recombinant human hematopoietic growth factors

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2897%2900038-5

7 January 2021

10.1016/S0959-8049(97)00038-5

Identifiers

DOI

1 reference

27 July 2017

1 reference